On Nov. 13, 2017, the Department of Transportation (DOT) published a final rule that, among other items, expands DOT’s current drug testing panel to include certain semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone). Testing for methylenedioxyethylamphetamine (MDEA) has been removed while methylenedioxyamphetamine (MDA) has been added as an initial test analyte.
The final rule also clarifies existing drug testing program provisions and definitions, makes technical amendments and removes the requirement for employers and Consortium/Third Party Administrators to submit blind specimens. The final rule becomes effective Jan. 1, 2018.
“The opioid crisis is a threat to public safety when it involves safety-sensitive employees involved in the operation of any kind of vehicle or transport,” said DOT Secretary Elaine L. Chao. “The ability to test for a broader range of opioids will advance transportation safety significantly and provide another deterrence to opioid abuse, which will better protect the public and ultimately save lives.”
Click here to read more from DOT.
Click here to read the final rule as published in the Federal Register.
Related News
- Get the Facts on the Union Pacific Arbitration Award from SBA 1208!
- New Jersey Passes Two New Pro-Labor Laws Backed by SMART-TD
- VILP Enrollment Extended Through September 26!
- FRA Expands Bridge Safety Oversight
- Rep. Lawler’s Transit Funding Flexibility Act of 2025 receives SMART-TD Endorsement
- Join Railroaders from Across the Country for Houston Rail Labor Solidarity Rally!
- Registration Open for Atlanta Regional Training Seminar
- SMART Railroad, Mechanical and Engineering Department members on Union Pacific unanimously ratify tentative agreement
- SMART Canada statement on Labour Day
- 2025 Labor Day Message from SMART-TD President Jeremy Ferguson